- A new daily weight-loss pill, orforglipron, has shown promising results in a trial, with participants losing an average of 16 pounds (7.2 kilograms) over nine months.
- The pill is being developed by Eli Lilly and could potentially rival injectable weight-loss drugs like Ozempic.
- Orforglipron is taken orally and doesn't have restrictions on food or water intake.
- It's being explored as a treatment for obesity, type 2 diabetes, obstructive sleep apnoea, and hypertension.
- The demand for weight-loss medications has surged recently, leading to increased prices and stricter regulations.
IN FULL